📋 Clinical Overview

Dinoprostone is a synthetic prostaglandin E2 (PGE2) analogue used primarily in obstetrics and gynecology for cervical ripening and induction of labor. The 10mg formulation is specifically designed as a controlled-release vaginal insert, providing a sustained release of the drug over 12 hours. It mimics the natural prostaglandins produced by the body to prepare the cervix for delivery.

💊 Dosage & Administration

Adult: One 10mg vaginal insert placed high in the posterior vaginal fornix. It should remain in place for 12 hours to allow for complete drug release or until the onset of active labor, uterine hyperstimulation, or fetal distress, whichever occurs first.

Note: 1. Administer ONLY in a hospital setting with obstetric care and neonatal resuscitation facilities. 2. Perform a pelvic exam to assess Bishop score and rule out contraindications. 3. Place the insert high in the posterior vaginal fornix. 4. The patient should remain supine for at least 30 minutes post-insertion. 5. Continuous electronic monitoring of fetal heart rate and uterine activity is mandatory. 6. The insert has a retrieval system (tape) for easy removal if necessary. 7. Remove upon onset of active labor, rupture of membranes, evidence of uterine hyperstimulation, fetal distress, or after 12 hours.

⚠️ Contraindications

Patients with known hypersensitivity to dinoprostone, prostaglandins, or any constituents of the vaginal insert.
Patients in whom vaginal delivery is contraindicated (e.g., placenta previa, vasa previa, active herpes genitalis).
Patients with unexplained vaginal bleeding during current pregnancy.
Patients with a history of cesarean section or major uterine surgery (due to high risk of uterine rupture).
Patients with fetal malpresentation.
Patients with obstetric emergencies where surgical intervention may be required.
Patients with evidence of fetal distress where delivery is not imminent.
Patients with ruptured membranes.
Patients already receiving intravenous oxytocic agents.
Multipara with six or more previous term pregnancies.

🔬 Mechanism of Action

Dinoprostone binds to specific prostaglandin E2 receptors (EP2 and EP3 subtypes) on cervical and uterine smooth muscle cells. This binding stimulates collagenase and elastase activity, leading to the breakdown of collagen fibers in the cervix (cervical ripening). It also increases the sensitivity of the myometrium to endogenous oxytocin, promoting coordinated uterine contractions.

🤕 Side Effects

Uterine hyperstimulation with or without fetal heart rate changes.
Vaginitis (burning, itching).
Nausea, vomiting.
Diarrhea.
Abdominal pain, back pain.
Fever (maternal pyrexia).
Fetal bradycardia or tachycardia.

🤰 Special Populations

Pregnancy: Pregnancy Category C (US FDA). Used specifically for induction of labor at term. Contraindicated in pregnancies where vaginal delivery is not intended. Not for use in earlier trimesters except for specific indications like missed abortion under strict supervision.

Driving: Not applicable. Patient is hospitalized.

🔄 Drug Interactions

Other Oxytocics (Oxytocin, Misoprostol)	Potentiates uterine contractions, significantly increasing the risk of uterine hyperstimulation, tetany, and rupture.	Contraindicated. Do not administer concurrently. A minimum interval of 30 minutes to 1 hour is recommended after dinoprostone removal.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs: Ibuprofen, Diclofenac, Aspirin)	May antagonize the uterine effects of dinoprostone by inhibiting prostaglandin synthesis.	Major
Corticosteroids	Theoretical increased risk of gastrointestinal ulceration.	Moderate
Antihypertensives	Dinoprostone may have vasodepressor effects; enhanced hypotensive effect possible.	Moderate

Cerviprime